117 related articles for article (PubMed ID: 11256484)
1. Pharmacokinetic differences between lansoprazole enantiomers and contribution of cytochrome P450 isoforms to enantioselective metabolism of lansoprazole in dogs.
Masa K; Hamada A; Arimori K; Fujii J; Nakano M
Biol Pharm Bull; 2001 Mar; 24(3):274-7. PubMed ID: 11256484
[TBL] [Abstract][Full Text] [Related]
2. Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes.
Katsuki H; Hamada A; Nakamura C; Arimori K; Nakano M
Eur J Clin Pharmacol; 2001 Dec; 57(10):709-15. PubMed ID: 11829200
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic differences between lansoprazole enantiomers in rats.
Arimori K; Yasuda K; Katsuki H; Nakano M
J Pharm Pharmacol; 1998 Nov; 50(11):1241-5. PubMed ID: 9877309
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic differences between pantoprazole enantiomers in rats.
Xie Z; Zhang Y; Xu H; Zhong D
Pharm Res; 2005 Oct; 22(10):1678-84. PubMed ID: 16180125
[TBL] [Abstract][Full Text] [Related]
5. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.
Kim KA; Shon JH; Park JY; Yoon YR; Kim MJ; Yun DH; Kim MK; Cha IJ; Hyun MH; Shin JG
Clin Pharmacol Ther; 2002 Jul; 72(1):90-9. PubMed ID: 12152007
[TBL] [Abstract][Full Text] [Related]
6. Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans.
Katsuki H; Yagi H; Arimori K; Nakamura C; Nakano M; Katafuchi S; Fujioka Y; Fujiyama S
Pharm Res; 1996 Apr; 13(4):611-5. PubMed ID: 8710755
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Eur J Clin Pharmacol; 2004 Nov; 60(9):623-8. PubMed ID: 15448955
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
Andersson T
Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
[TBL] [Abstract][Full Text] [Related]
9. Oxidative metabolism of lansoprazole by human liver cytochromes P450.
Pichard L; Curi-Pedrosa R; Bonfils C; Jacqz-Aigrain E; Domergue J; Joyeux H; Cosme J; Guengerich FP; Maurel P
Mol Pharmacol; 1995 Feb; 47(2):410-8. PubMed ID: 7870052
[TBL] [Abstract][Full Text] [Related]
10. Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes.
Kim KA; Kim MJ; Park JY; Shon JH; Yoon YR; Lee SS; Liu KH; Chun JH; Hyun MH; Shin JG
Drug Metab Dispos; 2003 Oct; 31(10):1227-34. PubMed ID: 12975331
[TBL] [Abstract][Full Text] [Related]
11. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.
Sohn DR; Kwon JT; Kim HK; Ishizaki T
Clin Pharmacol Ther; 1997 May; 61(5):574-82. PubMed ID: 9164419
[TBL] [Abstract][Full Text] [Related]
12. Effect of clarithromycin and other macrolides on the sulfoxidation and 5-hydroxylation of lansoprazole in dogs.
Masa K; Arimori K; Nakayama T; Miyamoto S; Fujii J; Nakano M
Biol Pharm Bull; 1999 May; 22(5):504-9. PubMed ID: 10375172
[TBL] [Abstract][Full Text] [Related]
13. Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro.
Liu KH; Kim MJ; Shon JH; Moon YS; Seol SY; Kang W; Cha IJ; Shin JG
Xenobiotica; 2005 Jan; 35(1):27-38. PubMed ID: 15788366
[TBL] [Abstract][Full Text] [Related]
14. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
Simon WA; Büdingen C; Fahr S; Kinder B; Koske M
Biochem Pharmacol; 1991 Jul; 42(2):347-55. PubMed ID: 1650212
[TBL] [Abstract][Full Text] [Related]
15. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
[TBL] [Abstract][Full Text] [Related]
16. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
17. Stereoselective disposition of proton pump inhibitors.
Andersson T; Weidolf L
Clin Drug Investig; 2008; 28(5):263-79. PubMed ID: 18407713
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
[TBL] [Abstract][Full Text] [Related]
19. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
[TBL] [Abstract][Full Text] [Related]
20. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Br J Clin Pharmacol; 2005 Jul; 60(1):61-8. PubMed ID: 15963095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
